

# Simon P Robinson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9144973/publications.pdf>

Version: 2024-02-01

133  
papers

7,478  
citations

109321

35  
h-index

56724

83  
g-index

136  
all docs

136  
docs citations

136  
times ranked

12884  
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. <i>Science</i> , 2018, 359, 920-926.	12.6	1,199
2	Imaging biomarker roadmap for cancer studies. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 169-186.	27.6	792
3	Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. <i>International Journal of Radiation Biology</i> , 2006, 82, 699-757.	1.8	561
4	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R92.	5.0	320
5	The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma. <i>Cancer Cell</i> , 2012, 22, 117-130.	16.8	270
6	Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. <i>Microvascular Research</i> , 2005, 69, 56-63.	2.5	254
7	Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma. <i>Cancer Cell</i> , 2013, 24, 75-89.	16.8	240
8	Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease. <i>Cancer Cell</i> , 2015, 27, 72-84.	16.8	165
9	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. <i>Cancer Discovery</i> , 2020, 10, 942-963.	9.4	157
10	Model Free Approach to Kinetic Analysis of Real-Time Hyperpolarized <sup>13</sup> C Magnetic Resonance Spectroscopy Data. <i>PLoS ONE</i> , 2013, 8, e71996.	2.5	134
11	Oxygen-Enhanced MRI Accurately Identifies, Quantifies, and Maps Tumor Hypoxia in Preclinical Cancer Models. <i>Cancer Research</i> , 2016, 76, 787-795.	0.9	133
12	Tumor vascular architecture and function evaluated by non-invasive susceptibility MRI methods and immunohistochemistry. <i>Journal of Magnetic Resonance Imaging</i> , 2003, 17, 445-454.	3.4	130
13	The response of human tumors to carbogen breathing, monitored by gradient-recalled echo magnetic resonance imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 39, 697-701.	0.8	128
14	Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. <i>British Journal of Cancer</i> , 2003, 88, 1592-1597.	6.4	114
15	Noninvasive monitoring of carbogen-induced changes in tumor blood flow and oxygenation by functional magnetic resonance imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 33, 855-859.	0.8	113
16	Imaging tumour hypoxia with oxygen-enhanced MRI and BOLD MRI. <i>British Journal of Radiology</i> , 2019, 92, 20180642.	2.2	111
17	Applications of Magnetic Resonance in Model Systems: Tumor Biology and Physiology. <i>Neoplasia</i> , 2000, 2, 139-151.	5.3	110
18	Tumor R2* is a prognostic indicator of acute radiotherapeutic response in rodent tumors. <i>Journal of Magnetic Resonance Imaging</i> , 2004, 19, 482-488.	3.4	91

#	ARTICLE	IF	CITATIONS
19	Exploring the Biomechanical Properties of Brain Malignancies and Their Pathologic Determinants <i>In Vivo</i> with Magnetic Resonance Elastography. <i>Cancer Research</i> , 2015, 75, 1216-1224.	0.9	90
20	CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs. <i>Clinical Cancer Research</i> , 2012, 18, 5650-5661.	7.0	84
21	The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2011, 10, 2115-2123.	4.1	79
22	Magnetic resonance imaging techniques for monitoring changes in tumor oxygenation and blood flow. <i>Seminars in Radiation Oncology</i> , 1998, 8, 197-207.	2.2	78
23	Tumour response to hypercapnia and hyperoxia monitored by FLOOD magnetic resonance imaging. <i>NMR in Biomedicine</i> , 1999, 12, 98-106.	2.8	78
24	Intrinsic Susceptibility MR Imaging of Chemically Induced Rat Mammary Tumors: Relationship to Histologic Assessment of Hypoxia and Fibrosis. <i>Radiology</i> , 2010, 254, 110-118.	7.3	72
25	Preclinical Evaluation of Imaging Biomarkers for Prostate Cancer Bone Metastasis and Response to Cabozantinib. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju033.	6.3	59
26	Effects of overexpression of dimethylarginine dimethylaminohydrolase on tumor angiogenesis assessed by susceptibility magnetic resonance imaging. <i>Cancer Research</i> , 2003, 63, 4960-6.	0.9	57
27	Robust estimation of the apparent diffusion coefficient (ADC) in heterogeneous solid tumors. <i>Magnetic Resonance in Medicine</i> , 2009, 62, 420-429.	3.0	50
28	Current issues in the utility of <sup>19</sup> F nuclear magnetic resonance methodologies for the assessment of tumour hypoxia. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2004, 359, 987-996.	4.0	49
29	Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. <i>Clinical Cancer Research</i> , 2015, 21, 5100-5109.	7.0	49
30	Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastography. <i>British Journal of Cancer</i> , 2014, 110, 1727-1732.	6.4	48
31	Exploring $\hat{r}^{2*}$ and $\hat{r}^1$ as imaging biomarkers of tumor oxygenation. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 38, 429-434.	3.4	44
32	<i>In Vivo</i> Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis. <i>Cancer Research</i> , 2019, 79, 5382-5393.	0.9	42
33	Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors. <i>Oncotarget</i> , 2016, 7, 57525-57544.	1.8	42
34	Effects of different levels of hypercapnic hyperoxia on tumour $R_2^*$ and arterial blood gases. <i>Magnetic Resonance Imaging</i> , 2001, 19, 161-166.	1.8	41
35	Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. <i>Journal of Clinical Investigation</i> , 2020, 130, 5875-5892.	8.2	40
36	The Response of RIF-1 Fibrosarcomas to the Vascular-Disrupting Agent ZD6126 Assessed by <i>In Vivo</i> and <i>Ex Vivo</i> <sup>1</sup> H Magnetic Resonance Spectroscopy. <i>Neoplasia</i> , 2006, 8, 560-567.	5.3	36

#	ARTICLE	IF	CITATIONS
37	Hyperpolarized <sup>13</sup> C magnetic resonance detection of carboxypeptidase G2 activity. <i>Magnetic Resonance in Medicine</i> , 2009, 62, 1300-1304.	3.0	36
38	Rat Tumor Response to the Vascular-Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid as Measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Plasma 5-Hydroxyindoleacetic Acid Levels, and Tumor Necrosis. <i>Neoplasia</i> , 2006, 8, 199-206.	5.3	35
39	Investigating the Contribution of Collagen to the Tumor Biomechanical Phenotype with Noninvasive Magnetic Resonance Elastography. <i>Cancer Research</i> , 2019, 79, 5874-5883.	0.9	35
40	Single Dose of the Antivasular Agent, ZD6126 (N-Acetylcoichinol-O-Phosphate), Reduces Perfusion for at Least 96 Hours in the GH3 Prolactinoma Rat Tumor Model. <i>Neoplasia</i> , 2004, 6, 150-157.	5.3	34
41	Mapping Hypoxia in Renal Carcinoma with Oxygen-enhanced MRI: Comparison with Intrinsic Susceptibility MRI and Pathology. <i>Radiology</i> , 2018, 288, 739-747.	7.3	34
42	Tumor Dose Response to the Vascular Disrupting Agent, 5,6-Dimethylxanthenone-4-Acetic Acid, Using In vivo Magnetic Resonance Spectroscopy. <i>Clinical Cancer Research</i> , 2005, 11, 3705-3713.	7.0	33
43	Evaluation of Clinically Translatable MR Imaging Biomarkers of Therapeutic Response in the TH-MYCNTtransgenic Mouse Model of Neuroblastoma. <i>Radiology</i> , 2013, 266, 130-140.	7.3	33
44	Rapid modification of the bone microenvironment following short-term treatment with Cabozantinib in vivo. <i>Bone</i> , 2015, 81, 581-592.	2.9	33
45	p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance. <i>Cancer Research</i> , 2016, 76, 3025-3035.	0.9	33
46	Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI. <i>Clinical Cancer Research</i> , 2017, 23, 4233-4241.	7.0	33
47	A Longitudinal Study of R2* and R2 Magnetic Resonance Imaging Relaxation Rate Measurements in Murine Liver After a Single Administration of 3 Different Iron Oxide-Based Contrast Agents. <i>Investigative Radiology</i> , 2005, 40, 784-791.	6.2	32
48	Acute Tumor Response to ZD6126 Assessed by Intrinsic Susceptibility Magnetic Resonance Imaging. <i>Neoplasia</i> , 2005, 7, 466-474.	5.3	32
49	Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126. <i>Microvascular Research</i> , 2006, 71, 76-84.	2.5	32
50	Investigating Low-Velocity Fluid Flow in Tumors with Convection-MRI. <i>Cancer Research</i> , 2018, 78, 1859-1872.	0.9	32
51	Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E1267-76.	7.1	31
52	In vivo determination of tumor oxygenation during growth and in response to carbogen breathing using <sup>15</sup> C5-loaded alginate capsules as fluorine-19 magnetic resonance imaging oxygen sensors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 909-919.	0.8	28
53	Bayesian estimation of changes in transverse relaxation rates. <i>Magnetic Resonance in Medicine</i> , 2010, 64, 914-921.	3.0	28
54	Hypoxia and its therapeutic possibilities in paediatric cancers. <i>British Journal of Cancer</i> , 2021, 124, 539-551.	6.4	28

#	ARTICLE	IF	CITATIONS
55	Modification of Tumour Perfusion and Oxygenation Monitored by Gradient Recalled Echo MRI and 31P MRS. , 1996, 9, 208-216.		27
56	Vessel Size Index Magnetic Resonance Imaging to Monitor the Effect of Antivascular Treatment in a Rodent Tumor Model. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1470-1476.	0.8	27
57	Active site mutant dimethylarginine dimethylaminohydrolase 1 expression confers an intermediate tumour phenotype in C6 gliomas. Journal of Pathology, 2011, 225, 344-352.	4.5	27
58	Repeatability and sensitivity of measurements in patients with head and neck squamous cell carcinoma at 3T. Journal of Magnetic Resonance Imaging, 2016, 44, 72-80.	3.4	27
59	Susceptibility Contrast Magnetic Resonance Imaging Determination of Fractional Tumor Blood Volume: A Noninvasive Imaging Biomarker of Response to the Vascular Disrupting Agent ZD6126. International Journal of Radiation Oncology Biology Physics, 2007, 69, 872-879.	0.8	26
60	Monitoring the Vascular Response and Resistance to Sunitinib in Renal Cell Carcinoma <i>In Vivo</i> with Susceptibility Contrast MRI. Cancer Research, 2017, 77, 4127-4134.	0.9	26
61	Overexpression of Dimethylarginine Dimethylaminohydrolase Enhances Tumor Hypoxia: An Insight into the Relationship of Hypoxia and Angiogenesis <i>In Vivo</i> . Neoplasia, 2004, 6, 401-411.	5.3	25
62	1 H NMR and hyperpolarized 13 C NMR assays of pyruvate→lactate: a comparative study. NMR in Biomedicine, 2013, 26, 1321-1325.	2.8	25
63	Improving apparent diffusion coefficient estimates and elucidating tumor heterogeneity using Bayesian adaptive smoothing. Magnetic Resonance in Medicine, 2011, 65, 438-447.	3.0	24
64	Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737). Journal of Medicinal Chemistry, 2016, 59, 5221-5237.	6.4	24
65	The effects of tumor-derived platelet-derived growth factor on vascular morphology and function <i>in vivo</i> revealed by susceptibility MRI. International Journal of Cancer, 2008, 122, 1548-1556.	5.1	23
66	Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI. British Journal of Cancer, 2013, 109, 1562-1569.	6.4	22
67	Correlation of Ultrasound Shear Wave Elastography with Pathological Analysis in a Xenographic Tumour Model. Scientific Reports, 2017, 7, 165.	3.3	21
68	Characterization of a Novel Mouse Model of Multiple Myeloma and Its Use in Preclinical Therapeutic Assessment. PLoS ONE, 2013, 8, e57641.	2.5	21
69	Longitudinal <i>in vivo</i> susceptibility contrast MRI measurements of LS174T colorectal liver metastasis in nude mice. Journal of Magnetic Resonance Imaging, 2008, 28, 1451-1458.	3.4	19
70	Non-invasive <i>in vivo</i> imaging of vessel calibre in orthotopic prostate tumour xenografts. International Journal of Cancer, 2012, 130, 1284-1293.	5.1	19
71	Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling. British Journal of Cancer, 2016, 115, 691-702.	6.4	19
72	Detection of the Prodrug-Activating Enzyme Carboxypeptidase G2 Activity with Chemical Exchange Saturation Transfer Magnetic Resonance. Molecular Imaging and Biology, 2014, 16, 152-157.	2.6	18

#	ARTICLE	IF	CITATIONS
73	Effect of Gd <sup>3+</sup> DTPA-BMA on choline signals of HT29 tumors detected by in vivo <sup>1</sup> H MRS. <i>Journal of Magnetic Resonance Imaging</i> , 2008, 28, 1201-1208.	3.4	17
74	Reduced Warburg Effect in Cancer Cells Undergoing Autophagy: Steady-State <sup>1</sup> H-MRS and Real-Time Hyperpolarized <sup>13</sup> C-MRS Studies. <i>PLoS ONE</i> , 2014, 9, e92645.	2.5	17
75	MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma. <i>Oncotarget</i> , 2020, 11, 2141-2159.	1.8	17
76	MRI measurements of vessel calibre in tumour xenografts: Comparison with vascular corrosion casting. <i>Microvascular Research</i> , 2012, 84, 323-329.	2.5	16
77	Intrinsic Susceptibility MRI Identifies Tumors with ALKF1174L Mutation in Genetically-Engineered Murine Models of High-Risk Neuroblastoma. <i>PLoS ONE</i> , 2014, 9, e92886.	2.5	16
78	Assessment of Tumor Response to the Vascular Disrupting Agents 5,6-Dimethylxanthenone-4-Acetic Acid or Combretastatin-A4-Phosphate by Intrinsic Susceptibility Magnetic Resonance Imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1238-1245.	0.8	15
79	Apparent diffusion coefficient is highly reproducible on preclinical imaging systems: Evidence from a seven-center multivendor study. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 42, 1759-1764.	3.4	15
80	Investigating the role of tumour cell derived <i>iNOS</i> on tumour growth and vasculature <i>in vivo</i> using a tetracycline regulated expression system. <i>International Journal of Cancer</i> , 2016, 138, 2678-2687.	5.1	15
81	Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	15
82	Noninvasive MRI Native T1 Mapping Detects Response to <i>MYCN</i> -targeted Therapies in the Th- <i>MYCN</i> Model of Neuroblastoma. <i>Cancer Research</i> , 2020, 80, 3424-3435.	0.9	15
83	DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition. <i>Cancer Discovery</i> , 2022, 12, 712-729.	9.4	15
84	Immunohistochemical assessment of intrinsic and extrinsic markers of hypoxia in reproductive tissue: differential expression of HIF1 $\alpha$ and HIF2 $\alpha$ in rat oviduct and endometrium. <i>Journal of Molecular Histology</i> , 2011, 42, 341-354.	2.2	14
85	Evaluation and Immunohistochemical Qualification of Carbogen-Induced $\Delta R_2^*$ as a Noninvasive Imaging Biomarker of Improved Tumor Oxygenation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 160-167.	0.8	14
86	Preclinical transgenic and patient-derived xenograft models recapitulate the radiological features of human adamantinomatous craniopharyngioma. <i>Brain Pathology</i> , 2018, 28, 475-483.	4.1	14
87	Evaluation of the Response of Intracranial Xenografts to VEGF Signaling Inhibition Using Multiparametric MRI. <i>Neoplasia</i> , 2017, 19, 684-694.	5.3	13
88	MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment. <i>Cancer Research</i> , 2019, 79, 2978-2991.	0.9	13
89	Enhanced Uptake of Ifofamide into GH3 Prolactinomas with Hypercapnic Hyperoxic Gases Monitored In Vivo by <sup>31</sup> P MRS. <i>Neoplasia</i> , 2002, 4, 539-543.	5.3	11
90	Investigating temporal fluctuations in tumor vasculature with combined carbogen and ultrasmall superparamagnetic iron oxide particle (CUSPIO) imaging. <i>Magnetic Resonance in Medicine</i> , 2011, 66, 227-234.	3.0	11

#	ARTICLE	IF	CITATIONS
91	Noninvasive detection of carboxypeptidase G2 activity <i>in vivo</i> . <i>NMR in Biomedicine</i> , 2011, 24, 343-350.	2.8	11
92	Investigating intracranial tumour growth patterns with multiparametric MRI incorporating Gd-DTPA and USPIO-enhanced imaging. <i>NMR in Biomedicine</i> , 2016, 29, 1608-1617.	2.8	11
93	False-negative MRI biomarkers of tumour response to targeted cancer therapeutics. <i>British Journal of Cancer</i> , 2012, 106, 1960-1966.	6.4	10
94	Detecting human melanoma cell re-differentiation following BRAF or heat shock protein 90 inhibition using photoacoustic and magnetic resonance imaging. <i>Scientific Reports</i> , 2017, 7, 8215.	3.3	10
95	A Multi-Parametric Imaging Investigation of the Response of C6 Glioma Xenografts to MLN0518 (Tandutinib) Treatment. <i>PLoS ONE</i> , 2013, 8, e63024.	2.5	10
96	Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas. <i>International Journal of Cancer</i> , 2012, 131, 1854-1862.	5.1	9
97	Pre-clinical imaging of transgenic mouse models of neuroblastoma using a dedicated 3-element solenoid coil on a clinical 3T platform. <i>British Journal of Cancer</i> , 2017, 117, 791-800.	6.4	9
98	Evaluating Imaging Biomarkers of Acquired Resistance to Targeted EGFR Therapy in Xenograft Models of Human Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2018, 8, 271.	2.8	9
99	Assessment of the direct effects of DDAH I on tumour angiogenesis <i>in vivo</i> . <i>Angiogenesis</i> , 2018, 21, 737-749.	7.2	7
100	The Effects of Tumour Blood Flow and Oxygenation Modifiers on Subcutaneous Tumours as Determined by NIRS. , 2005, 566, 75-81.		6
101	Modulation of renal oxygenation and perfusion in rat kidney monitored by quantitative diffusion and blood oxygen level dependent magnetic resonance imaging on a clinical 1.5T platform. <i>BMC Nephrology</i> , 2016, 17, 142.	1.8	6
102	Immunoassays for the quantification of <i>ALK</i> and phosphorylated <i>ALK</i> support the evaluation of on-target <i>ALK</i> inhibitors in neuroblastoma. <i>Molecular Oncology</i> , 2017, 11, 996-1006.	4.6	6
103	Issues in GRE & Se Magnetic Resonance Imaging to Probe Tumor Oxygenation. <i>Advances in Experimental Medicine and Biology</i> , 2003, 530, 441-448.	1.6	6
104	The importance of tumor metabolism in cancer prognosis and therapy; pre-clinical studies on rodent tumors with agents that improve tumor oxygenation. <i>Advances in Enzyme Regulation</i> , 2002, 42, 131-141.	2.6	5
105	Investigating the Vascular Phenotype of Subcutaneously and Orthotopically Propagated PC3 Prostate Cancer Xenografts Using Combined Carbogen Ultrasmall Superparamagnetic Iron Oxide MRI. <i>Topics in Magnetic Resonance Imaging</i> , 2016, 25, 237-243.	1.2	5
106	Multi-Channel Optical Coherence Elastography Using Relative and Absolute Shear-Wave Time of Flight. <i>PLoS ONE</i> , 2017, 12, e0169664.	2.5	4
107	Characterisation of fibrosis in chemically-induced rat mammary carcinomas using multi-modal endogenous contrast MRI on a 1.5T clinical platform. <i>European Radiology</i> , 2018, 28, 1642-1653.	4.5	3
108	Detecting microvascular changes in the mouse spleen using optical computed tomography. <i>Microvascular Research</i> , 2015, 101, 96-102.	2.5	2

#	ARTICLE	IF	CITATIONS
109	Abstract 1488: In vivo magnetic resonance elastography in pediatric brain tumor models. , 2015, , .		2
110	Abstract 3271: Novel orthotopic pediatric high grade glioma xenografts evaluated with magnetic resonance imaging mimic human disease. Cancer Research, 2015, 75, 3271-3271.	0.9	2
111	Abstract 4459: Evaluating imaging biomarkers of acquired resistance to targeted EGFR therapy in xenograft models of human squamous cell carcinoma of the head and neck (SCCHN).. , 2013, , .		2
112	Non-invasive molecular profiling of cancer using photoacoustic imaging of functionalized gold nanorods. , 2014, , .		1
113	Tumour response to hypercapnia and hyperoxia monitored by FLOOD magnetic resonance imaging. NMR in Biomedicine, 1999, 12, 98-106.	2.8	1
114	Lessons from Animal Imaging in Preclinical Models. , 2010, , 95-116.		1
115	PCM-08: IN VIVO MAGNETIC RESONANCE IMAGING IDENTIFIES CLINICAL PHENOTYPES OF PAEDIATRIC GLIOBLASTOMA IN AN ORTHOTOPIC MOUSE XENOGRFT MODEL. Neuro-Oncology, 2016, 18, iii140.4-iii141.	1.2	0
116	HG-99A PATIENT-DERIVED PAEDIATRIC HIGH GRADE GLIOMA AND DIPG CELL CULTURE PANEL RECAPITULATING THE GENOTYPIC AND PHENOTYPIC DIVERSITY OF THE DISEASE. Neuro-Oncology, 2016, 18, iii71.3-iii71.	1.2	0
117	DIPG-25. GENETIC ALTERATIONS TARGETING THE MAPK PATHWAY CONFERS PRECLINICAL SENSITIVITY TO TRAMETINIB IN A CO-CLINICAL TRIAL IN DIPG. Neuro-Oncology, 2019, 21, ii74-ii74.	1.2	0
118	TMOD-03. A NOVEL MB GR3 TRANSGENIC MOUSE MODEL IS GENERATED BY <i>MYCN</i> AND <i>P53</i> DEFECTS IN VENTRICULAR ZONE PROGENITORS.. Neuro-Oncology, 2021, 23, i36-i36.	1.2	0
119	Abstract B257: Chronic dosing with MLN0518 (Tandutinib), a small molecule PDGFR $\alpha/\beta$ inhibitor, reduces tumor growth, hypoxia, and perfusion in C6 glioma xenografts: An investigation using immunohistochemical and MRI methods. , 2009, , .		0
120	Abstract C90: An MRI and histological investigation of the acute response of orthotopic PC3 prostate tumors to the HIF pathway inhibitor NSC-134754 in vivo. , 2009, , .		0
121	Abstract 4189: Characterization of tumor progression and chemoresponse in a novel transgenic mouse model of neuroblastoma (TH-MYCN) using magnetic resonance imaging. , 2010, , .		0
122	Abstract 4074: The effects of the HIF pathway inhibitor NSC-134754 on glucose metabolism. , 2011, , .		0
123	Abstract 3788: Autophagy induced by DCA, PI3K inhibition or starvation results in reduced lactate production measured in real-time by DNP 13C MRS. , 2011, , .		0
124	Abstract 5290: Imaging biomarkers of response to chemotherapy in neuroblastoma. , 2011, , .		0
125	Abstract 4345: AZD8055, a combined TORC1/TORC2 inhibitor regulates Mycn protein expression and prevents neuroblastoma growth in vitro and in vivo. , 2011, , .		0
126	Abstract 3924: Multimodality imaging investigation of response to cabozantinib in a VCaP model of prostate bone metastasis.. , 2013, , .		0



#	ARTICLE	IF	CITATIONS
127	Abstract 1559: Evaluation of MR imaging biomarkers of the vascular and infiltrative phenotype in intracranial MDA-MB-231 tumors.. , 2013, , .		0
128	Abstract 5037: Intrinsic susceptibility magnetic resonance imaging identifies tumors with ALKF1174L mutation in transgenic murine models of high-risk neuroblastoma.. , 2013, , .		0
129	Abstract LB-201: MYC and TP53 defects interact at medulloblastoma relapse to define rapidly progressive disease and can be targeted therapeutically. , 2014, , .		0
130	Abstract 1372: Acquired resistance to sunitinib is not associated with functional re-vascularization in 786-O renal cell carcinoma xenografts. , 2015, , .		0
131	Abstract 2930: Differential tumour response to birinapant and irinotecan revealed by non-invasive MRI. , 2015, , .		0
132	Abstract 491: Tumor response to cabozantinib in the TH-MYCN GEM model of neuroblastoma. , 2015, , .		0
133	Abstract 4108: Longitudinal diffusion-weighted MRI assessment of NRAS mutant melanoma response to dual RAF-MEK inhibition reveals differences associated with collagen deposition. , 2018, , .		0